| Autor: |
Leroux-Roels G; Center for Vaccinology, Ghent University and Hospital, De Pintelaan 185, B-9000 Ghent, Belgium., Depla E, Hulstaert F, Tobback L, Dincq S, Desmet J, Desombere I, Maertens G |
| Jazyk: |
angličtina |
| Zdroj: |
Vaccine [Vaccine] 2004 Aug 13; Vol. 22 (23-24), pp. 3080-6. |
| DOI: |
10.1016/j.vaccine.2004.02.002 |
| Abstrakt: |
The tolerability and immunogenicity of the hepatitis C virus E1 protein as a candidate vaccine was examined in a Phase I, single-arm study. Twenty healthy male volunteers were injected in the deltoid muscle at weeks 0, 3 and 6 with 20 microg recombinant E1 adsorbed on alum. A fourth (booster) dose was administered to 19 subjects at week 26. The candidate therapeutic vaccine was well tolerated. Three vaccine doses induced a clear humoral anti-E1 response that was boosted by a fourth dose. A strong, specific cellular immune response towards E1 was elicited in all vaccine recipients, which included a clear Th1 type response in all but one of the subjects. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect